Related Experiment Videos
The implantable cardioverter-defibrillator.
1University of Washington, AVID Clinical Trial Center, Seattle 98105, USA.
Clinical Cardiology
|May 10, 2000
Summary
The implantable cardioverter-defibrillator (ICD) is a superior treatment for ventricular arrhythmias, especially for patients with a history of cardiac events. Clinical trials confirm its effectiveness in preventing sudden cardiac death.
Area of Science:
- Cardiology
- Electrophysiology
Background:
- Ventricular arrhythmias are a leading cause of cardiovascular mortality.
- Treatment has shifted from antiarrhythmic drugs to implanted devices like the implantable cardioverter-defibrillator (ICD).
Purpose of the Study:
- To evaluate the efficacy of the implantable cardioverter-defibrillator (ICD) in managing serious ventricular arrhythmias.
- To compare ICD therapy with conventional antiarrhythmic drug therapy.
Main Methods:
- Review of controlled clinical trials and therapeutic outcomes.
- Analysis of patient populations including those with ventricular fibrillation, sustained ventricular tachycardia, and post-myocardial infarction survivors.
Main Results:
- The ICD is the preferred therapy for ventricular fibrillation without reversible causes and for sustained ventricular tachycardia causing syncope.
- In primary prevention, ICDs are superior to antiarrhythmic drugs for specific high-risk post-myocardial infarction patients.
Conclusions:
- The implantable cardioverter-defibrillator (ICD) represents a major advancement in treating life-threatening ventricular arrhythmias.
- Further research is needed to establish the survival benefits of ICDs in other patient groups.